CBR Division, Defence Science and Technology Laboratorygrid.417845.b (Dstl), Porton Down, Salisbury, Wiltshire, United Kingdom.
Animal and Plant Health Agency, Weybridge, Addlestone, Surrey, United Kingdom.
J Virol. 2022 Feb 23;96(4):e0173921. doi: 10.1128/JVI.01739-21. Epub 2021 Dec 15.
Two strains of Middle East respiratory syndrome coronavirus (MERS-CoV), England 1 and Erasmus Medical Centre/2012 (EMC/2012), were used to challenge common marmosets (Callithrix jacchus) by three routes of infection: aerosol, oral, and intranasal. Animals challenged by the intranasal and aerosol routes presented with mild, transient disease, while those challenged by the oral route presented with a subclinical immunological response. Animals challenged with MERS-CoV strain EMC/2012 by the aerosol route responded with primary and/or secondary pyrexia. Marmosets had minimal to mild multifocal interstitial pneumonia, with the greatest relative severity being observed in animals challenged by the aerosol route. Viable virus was isolated from the host in throat swabs and lung tissue. The transient disease described is consistent with a successful host response and was characterized by the upregulation of macrophage and neutrophil function observed in all animals at the time of euthanasia. Middle East respiratory syndrome is caused by a human coronavirus, MERS-CoV, similar to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Humans typically exhibit fever, cough, shortness of breath, gastrointestinal issues, and breathing difficulties, which can lead to pneumonia and/or renal complications. This emerging disease resulted in the first human lethal cases in 2012 and has a case fatality rate of approximately 36%. Consequently, there is a need for medical countermeasures and appropriate animal models for their assessment. This work has demonstrated the requirement for higher concentrations of virus to cause overt disease. Challenge by the aerosol, intranasal, and oral routes resulted in no or mild disease, but all animals had an immunological response. This shows that an appropriate early immunological response is able to control the disease.
两种中东呼吸综合征冠状病毒(MERS-CoV)株,英国 1 株和伊拉斯谟医疗中心/2012 株(EMC/2012 株),通过三种感染途径:气溶胶、口服和鼻腔内,对普通狨猴(Callithrix jacchus)进行了挑战。通过鼻腔内和气溶胶途径感染的动物表现出轻度、短暂的疾病,而通过口服途径感染的动物则表现出亚临床免疫反应。通过气溶胶途径用 MERS-CoV 株 EMC/2012 株感染的动物出现原发性和/或继发性发热。狨猴有最小至轻度多灶性间质性肺炎,以通过气溶胶途径感染的动物观察到的相对严重程度最大。从宿主的咽喉拭子和肺组织中分离出有活力的病毒。描述的短暂疾病与成功的宿主反应一致,并以所有动物在安乐死时观察到的巨噬细胞和中性粒细胞功能上调为特征。中东呼吸综合征是由一种人类冠状病毒,MERS-CoV,类似于严重急性呼吸综合征冠状病毒 2(SARS-CoV-2)引起的。人类通常表现出发热、咳嗽、呼吸急促、胃肠道问题和呼吸困难,这可能导致肺炎和/或肾脏并发症。这种新兴疾病于 2012 年首次导致人类致命病例,死亡率约为 36%。因此,需要医疗对策和适当的动物模型来评估它们。这项工作表明需要更高浓度的病毒才能引起明显的疾病。通过气溶胶、鼻腔内和口服途径进行的挑战导致无或轻度疾病,但所有动物都有免疫反应。这表明适当的早期免疫反应能够控制疾病。